Protagonist Therapeutics saw a positive improvement to its Relative Strength (RS) Rating on Monday, rising from 69 to 74.
IBD's unique rating measures market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database.
History shows that the best stocks typically have an RS Rating of at least 80 in the early stages of their moves. See if Protagonist Therapeutics can continue to rebound and hit that benchmark.
How To Invest In Stocks In Both Bull And Bear Markets
Protagonist Therapeutics is trying to complete a consolidation with a 48.89 buy point. See if it can clear the breakout price in volume at least 40% above average.
The company showed 0% EPS growth last quarter. Revenue increased -100%.
Protagonist Therapeutics earns the No. 14 rank among its peers in the Medical-Ethical Drugs industry group. Phibro Animal Health, Novartis ADR and Jazz Pharmaceuticals are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
